Moalifeplus Registers Patent for Universal Vaccine Platform

Moalifeplus (CEO Han Sangjin) announced on October 22 that its independently developed next-generation universal vaccine platform technology has recently been granted a patent. With this achievement, Moalifeplus has secured both proprietary technological competitiveness in the field of infectious disease response and a foundation for entry into the global market.

The newly registered patent covers "a technology that simultaneously expresses the spike (S), nucleocapsid (N), and PgsA proteins of coronavirus using a replication-incompetent adenovirus." This multi-antigen-based platform can respond not only to COVID-19 variants but also to a broad range of infectious diseases such as seasonal influenza, and is regarded as a universal vaccine technology that overcomes the limitations of single-antigen vaccines.

Moalifeplus's vaccine is designed to block infection by inducing neutralizing antibodies against the spike protein and to maintain sustained and broad immune responses by enhancing cellular immunity through the nucleocapsid protein. In addition, by utilizing the PgsA protein to maximize the efficiency of the immune response, the company explains that the vaccine induces a powerful and long-lasting immune response capable of addressing variant viruses.

In fact, tests conducted at a domestic virus research institute on the COVID-19 Delta variant showed that the neutralizing antibody activity (ID50) of serum from vaccinated subjects averaged between 3,000 and 4,000. This is more than 10 times higher than the average of 300 to 500 observed with existing spike single-antigen vaccines, scientifically demonstrating broad protective efficacy against variant viruses.

Industry insiders are describing this patent registration as "a turning point for Moalifeplus to advance as a technology-driven platform company." As global pharmaceutical companies compete to secure the next-generation vaccine platform market, Moalifeplus is drawing attention as the only domestic company with proprietary technology that combines multi-antigen expression with PgsA cell membrane fixation technology.

A Moalifeplus representative stated, "This patent is a key technological achievement that enables us to respond to recurring infectious disease crises after COVID-19 with a new vaccine platform resilient to variants," adding, "We plan to actively pursue global market entry and technology transfer partnerships based on our multi-antigen universal vaccine platform."

Meanwhile, the global vaccine market was valued at approximately 72 billion dollars (about 100 trillion won) as of last year, and the World Health Organization (WHO) forecasts that universal vaccine platforms will become mainstream in the market within the next decade.

Moalifeplus explained that with this patent registration, the company has secured both technological competitiveness and high growth potential in the infectious disease response platform market.

This content was produced with the assistance of AI translation services.